Vericel - 24 Year Stock Price History | VCEL

Historical daily share price chart and data for Vericel since 1997 adjusted for splits. The latest closing stock price for Vericel as of September 27, 2021 is 49.16.
  • The all-time high Vericel stock closing price was 1410.08 on September 24, 1997.
  • The Vericel 52-week high stock price is 68.94, which is 40.2% above the current share price.
  • The Vericel 52-week low stock price is 18.09, which is 63.2% below the current share price.
  • The average Vericel stock price for the last 52 weeks is 44.24.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Vericel Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 51.4471 30.9300 67.8100 30.9300 49.1600 59.20%
2020 17.2506 17.4900 31.5000 7.2500 30.8800 77.47%
2019 17.4562 17.7300 20.2900 13.7700 17.4000 0.00%
2018 11.8845 5.9000 18.4400 5.7000 17.4000 219.27%
2017 3.5069 2.9000 6.0000 2.5000 5.4500 81.67%
2016 2.6384 2.5300 6.0800 1.7850 3.0000 16.28%
2015 3.0825 3.1500 3.9500 1.7100 2.5800 -15.13%
2014 3.5103 3.3900 6.4900 2.6100 3.0400 -5.88%
2013 11.9065 26.8000 28.2000 3.2100 3.2300 -87.18%
2012 36.9831 36.2000 52.8000 23.0000 25.2000 -30.77%
2011 50.2729 53.6000 65.4000 35.8000 36.4000 -28.91%
2010 36.4176 54.3040 84.0000 26.8000 51.2000 4.07%
2009 63.6713 84.7840 117.5040 41.6000 49.2000 -38.50%
2008 66.5577 85.1200 120.8000 25.6000 80.0000 -3.85%
2007 198.6193 198.4000 252.8000 83.2000 83.2000 -57.72%
2006 236.4725 337.6000 358.4000 177.6000 196.8000 -41.71%
2005 409.5067 219.2000 648.0000 219.2000 337.6000 48.59%
2004 177.3571 220.8000 267.2000 104.0000 227.2000 6.77%
2003 142.7683 75.2000 283.2000 40.0000 212.8000 182.98%
2002 85.7084 158.2400 168.0000 36.8000 75.2000 -52.04%
2001 197.2304 145.0080 384.0000 120.0000 156.8000 12.00%
2000 424.3533 125.0080 1240.0000 115.0080 140.0000 11.99%
1999 270.6114 440.0000 520.0000 70.0000 125.0080 -72.82%
1998 581.0724 760.0000 1020.0000 290.0800 460.0000 -34.29%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.292B $0.124B
Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29